Curia is investing more than $28 million to expand sterile active pharmaceutical ingredient manufacturing at its Valladolid site in Spain, adding capacity for steroid and non steroid products in a programme scheduled for completion during the fourth quarter of 2028.
The project began during the third quarter of 2026 and follows a $4 million upgrade to two existing aseptic suites at the same site. Together, the two programmes represent more than $32 million of recent investment in Valladolid’s sterile manufacturing infrastructure.
Curia’s 50,000 sq m campus carries out API and intermediate manufacturing using chemical synthesis alongside specialist steroid, hormone, high potency and sterile processing operations. More than 360 people work at the site, which includes around 100 cubic metres of steroid reactor capacity and 10 cubic metres dedicated to non steroid APIs and intermediates.
Sterile API manufacturing adds contamination control requirements beyond those applied to a conventional chemical intermediate. Material can meet its chemical purity specification and still become unusable if microorganisms, endotoxins or particulate matter enter the process after sterilisation.
Valladolid uses aseptic filtration and crystallisation to sterilise APIs under contained conditions. Filtration removes microbiological contamination from solution before the API is crystallised and isolated without exposing the product to an uncontrolled manufacturing environment.
The existing plant has two sterilisation lines, while Curia’s earlier $4 million programme converted the aseptic suites to fully closed processing. New isolators were installed alongside changes to HVAC, pharmaceutical utilities, automation and sterilisation in place equipment to align the operation with EU GMP Annex 1 expectations.
Annex 1 requires manufacturers to treat contamination control as a system rather than relying on final sterility testing. Airflow, equipment design, operator intervention, cleaning, sterilisation, utilities and environmental monitoring all influence contamination risk, so weaknesses at one stage cannot necessarily be corrected by controls applied later.
Closed processing removes some of those exposure routes by maintaining a physical barrier around product during critical operations. Isolators further separate employees from aseptic work, reducing the microbiological and particulate load introduced through direct intervention.
The new $28 million programme adds manufacturing capacity rather than concentrating solely on compliance improvements. Curia says the investment will support sterile steroid and non steroid API work from development through commercial scale, increasing the volume of material that can pass through Valladolid once the additional equipment is qualified.
Steroid manufacture introduces further containment requirements because many compounds are pharmacologically active at low concentrations. Facilities have to protect employees while preventing carryover between products, which makes segregation, cleaning verification and contained material handling central to the process design.
Valladolid has dedicated steroid and hormone facilities and can handle products across occupational exposure bands OEB1 to OEB5, with isolator technology used for higher potency OEB4 and OEB5 operations. Increasing containment as potency rises allows smaller exposure limits to be maintained while batches are charged, processed and recovered.
Particle engineering forms another part of the site’s manufacturing chain. Curia has more than 20 years of particle size control experience at Valladolid using controlled crystallisation, milling and micronisation, processes that can alter dissolution, flow and the way an API behaves during finished drug formulation.
Combining synthesis, sterile processing and particle control at one campus can reduce the number of transfers between manufacturing locations. Every external movement introduces logistics, scheduling, documentation and quality interfaces, while sterile products can also require specialised packaging and environmental controls during transport.
Integration does not remove the need to qualify each manufacturing stage independently. Pharmaceutical customers require validated equipment, analytical methods, batch documentation, change control and regulatory support, so additional physical capacity becomes commercially useful only after individual processes and products have been approved for the new equipment.
The Valladolid site has been inspected by authorities including the US Food and Drug Administration, Japan’s PMDA, the Spanish medicines agency and Brazil’s ANVISA. Its existing API portfolio provides a regulatory and commercial base for the investment rather than requiring Curia to establish sterile manufacturing capability from a new site.
Bringing regulated capacity into service generally takes longer than completing the building and equipment installation. Clean utilities, HVAC, controls, process equipment and analytical methods all have to demonstrate repeatable performance before commercial batches can be released.
The Q4 2028 completion target therefore covers a multiyear expansion whose qualification work will continue alongside normal manufacturing. Curia must install and commission the new infrastructure without disrupting existing programmes before customers can transfer or scale products into the additional capacity.
The earlier aseptic suite upgrade provides part of the contamination control architecture on which the larger project can build. Utilisation will ultimately depend on how many customer products are qualified, how quickly development projects progress into commercial batches and whether the additional sterile capacity can be operated consistently at the standards required across multiple regulatory markets.
